R-Pharm considers expanding in Japanese pharmaceutical market

4 October 2017

R-Pharm, one of Russia’s leading biotech firms, is considering expanding into the Japanese pharmaceutical market during the next several years.

Initially, this will achieved through the sales of two or three new drugs. This has been confirmed by chairman of the company Alexei Repik, reports The Pharma Letter’s local correspondent.

The list of the drugs which are planned for launch in Japan includes olokizumab, which is an original drug for the treatment of rheumatoid arthritis; RPH-104, an anti-inflammatory drug in the form of injections, as well as a bioanalogue of RPH-002, which is an antitumor drug for the treatment of head and neck cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK